Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Outlook Therapeutics, Inc.OTLK · Entity 608 | Director | June 02, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Outlook Therapeutics, Inc.
Report date June 02, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,167 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Purchase · Acquired 29,000 · Balance 66,167 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2026 Filed Jun 3, 2026 22:03 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 29,000 | $0.83 | $24,145.40 |
DisclosureSEC source: 0001649989-26-000005 · primary_doc.xml · nonDerivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,167 Read SEC document |
| May 26, 2026 Filed May 27, 2026 19:24 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 34,000 | $0.44 | $14,960.00 |
DisclosureSEC source: 0001649989-26-000003 · primary_doc.xml · nonDerivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,167 Read SEC document |
| October 03, 2025 Filed Oct 3, 2025 23:20 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 95,969 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001649989-25-000006 · primary_doc.xml · derivative · entry 2 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,969 Underlying: Common Stock · 95,969 shares Expires 2035-10-03 F2 · derivative.exercise_date: The options were granted under the 2024 Plan in lieu of $90,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 23:20 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 286,734 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001649989-25-000006 · primary_doc.xml · derivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,734 Underlying: Common Stock · 286,734 shares Expires 2035-10-01 F1 · derivative.exercise_date: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2026, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| October 03, 2024 Filed Oct 4, 2024 00:30 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 19,771 | $0.00 Strike: $5.25 | $0.00 |
DisclosureSEC source: 0001415889-24-024704 · form4-10032024_081007.xml · derivative · entry 3 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,771 Underlying: Common Stock · 19,771 shares Expires 2034-10-03 F3 · derivative.exercise_date: The options were granted under the 2024 Plan in lieu of $90,000 cash fees payable under the Issuer's Non-Employee Director Compensation Policy and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| October 01, 2024 Filed Oct 4, 2024 00:30 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 132,293 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001415889-24-024704 · form4-10032024_081007.xml · derivative · entry 2 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,293 Underlying: Common Stock · 132,293 shares Expires 2034-10-01 F2 · derivative.exercise_date: This option grant was made under the 2024 Plan and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| October 01, 2024 Filed Oct 4, 2024 00:30 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 56,636 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001415889-24-024704 · form4-10032024_081007.xml · derivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,636 Underlying: Common Stock · 56,636 shares Expires 2034-10-01 F1 · derivative.exercise_date: This option grant is an annual stock option grant under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan (the "2024 Plan") and shall fully vest on October 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2024 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| March 28, 2024 Filed Mar 29, 2024 14:39 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 1,881.7112 | $11.82 | $22,241.83 |
DisclosureSEC source: 0001415889-24-009394 · form4-03292024_020304.xml · nonDerivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,048.7112 F1 · price: The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $11.78 to $11.8249 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Reflects the Issuer's 1-for-20 reverse stock split effected on March 13, 2024. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 21:11 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 94,441 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001415889-24-007332 · form4-03082024_090358.xml · derivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,441 Underlying: Common Stock · 94,441 shares Expires 2034-03-07 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 7, 2025; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| October 04, 2023 Filed Oct 5, 2023 21:07 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 358,337 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001209191-23-052235 · doc4.xml · derivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 358,337 Underlying: Common Stock · 358,337 shares Expires 2033-10-04 F1 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $75,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2024, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| March 29, 2023 Filed Mar 31, 2023 21:50 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 41,065 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001209191-23-021913 · doc4.xml · derivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,065 Underlying: Common Stock · 41,065 shares Expires 2033-03-29 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 29,2024; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| October 07, 2022 Filed Oct 11, 2022 21:05 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 3,600 | $1.27 | $4,572.00 |
DisclosureSEC source: 0001209191-22-053354 · doc4.xml · nonDerivative · entry 2 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,343 Read SEC document |
| October 06, 2022 Filed Oct 11, 2022 21:05 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 29,743 | $1.29 | $38,368.47 |
DisclosureSEC source: 0001209191-22-053354 · doc4.xml · nonDerivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,743 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.279 - $1.2915, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 05, 2022 Filed Oct 7, 2022 20:39 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 71,998 | $0.00 Strike: $1.25 | $0.00 |
DisclosureSEC source: 0001209191-22-053123 · doc4.xml · derivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,998 Underlying: Common Stock · 71,998 shares Expires 2032-10-05 F1 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $75,000 cash fees payable under the Issuer's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2023, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| March 23, 2022 Filed Mar 24, 2022 21:39 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 21,878 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001209191-22-020952 · doc4.xml · derivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,878 Underlying: Common Stock · 21,878 shares Expires 2032-03-23 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall fully vest on the earlier of (i) March 23,2023; or (ii) the date of the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person providing continuous service to the Issuer on such date. In addition, the shares underlying the options are subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer immediately prior to such Change in Control. Read SEC document |
| December 02, 2021 Filed Dec 2, 2021 22:09 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 10,000 | $1.39 | $13,900.00 |
DisclosureSEC source: 0001209191-21-067650 · doc4.xml · nonDerivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.385 - $1.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 21:06 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 47,335 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-21-059950 · doc4.xml · derivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,335 Underlying: Common Stock · 47,335 shares Expires 2031-10-05 F1 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $82,500 cash fees payable under the Issuers's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 23:56 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 10,000 | $1.82 | $18,200.00 |
DisclosureSEC source: 0001209191-21-027685 · doc4.xml · nonDerivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| March 24, 2021 Filed Mar 26, 2021 22:08 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 20,873 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001209191-21-023283 · doc4.xml · derivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,873 Underlying: Common Stock · 20,873 shares Expires 2031-03-24 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on March 24, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| October 05, 2020 Filed Oct 5, 2020 22:47 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 160,474 | $0.51 Strike: $0.71 | $82,499.68 |
DisclosureSEC source: 0001209191-20-053873 · doc4.xml · derivative · entry 2 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,474 Underlying: Common Stock · 160,474 shares Expires 2030-10-05 F2 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $82,500 cash fees payable under the Issuers's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 22:47 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 290,372 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001209191-20-053873 · doc4.xml · derivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,372 Underlying: Common Stock · 290,372 shares Expires 2030-10-01 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on October 1, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| September 22, 2020 Filed Sep 22, 2020 21:14 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | PurchaseCommon Stock | 10,000 | $0.72 | $7,245.00 |
DisclosureSEC source: 0001209191-20-051507 · doc4.xml · nonDerivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| July 17, 2020 Filed Jul 21, 2020 22:06 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-20-043218 · doc4.xml · derivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 135,000 shares Expires 2030-07-17 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on July 17, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| March 19, 2020 Filed Mar 20, 2020 21:52 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001209191-20-020509 · doc4.xml · derivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-03-19 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on March 19, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 01:29 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 5,980 | $0.99 Strike: $0.88 | $5,892.09 |
DisclosureSEC source: 0001209191-20-002167 · doc4.xml · derivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,980 Underlying: Common Stock · 5,980 shares Expires 2030-01-02 F1 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $5,892.86 cash fees payable under the Issuers's non-employee Director compensation program and vest in three equal quarterly installments on the last day of each remaining fiscal quarter (3/31, 6/30 and 9/30) such that they are vested in full on September 30, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 22:11 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 80,176 | $0.99 Strike: $1.40 | $78,997.41 |
DisclosureSEC source: 0001209191-19-052712 · doc4.xml · derivative · entry 2 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,176 Underlying: Common Stock · 80,176 shares Expires 2029-10-03 F2 · derivative.exercise_date: The options were granted under the 2015 Plan in lieu of $79,000 cash fees payable under the Issuers's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 22:11 UTC | Outlook Therapeutics, Inc. OTLK · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001209191-19-052712 · doc4.xml · derivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-10-03 F1 · derivative.exercise_date: The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on the one year anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan. Read SEC document |
| October 31, 2017 Filed Nov 2, 2017 22:13 UTC | Outlook Therapeutics, Inc. ONS · Entity 608 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001209191-17-058966 · doc4.xml · derivative · entry 1 Haddadin Yezan Munther · CIK 0001718004 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-10-31 F1 · derivative.exercise_date: 33.33% of the shares underlying the option shall vest on each of the first, second and third anniversaries of the grant date, such that 100% of the shares underlying the option shall be vested on October 31, 2020, subject to the Reporting Person providing continued service through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.